CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.08
+0.02 (+0.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.06
Open2.07
Bid1.62 x 900
Ask2.10 x 1800
Day's Range1.98 - 2.10
52 Week Range0.85 - 2.93
Volume127,581
Avg. Volume181,209
Market Cap165.172M
Beta (3Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.64
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.56
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the Company will participate in a symposium entitled “Exploring the Antibiotic Pipeline 2018” and   present new data on its lead drug candidate, CF-301 (exebacase), at IDWeek 2018, to be held from October 3-7, 2018, in San Francisco. The symposium will review novel antibiotics in the pipeline including mechanism of action and clinical applications, and the possible role of novel therapies against antibiotic-resistant organisms, and will evaluate data from new antimicrobial molecules in development. “We are pleased to have been invited by the conference organizers to participate in the IDWeek pipeline update this year,” said Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer.

  • Zacks Small Cap Research24 days ago

    CFRX: Enrollment for Phase 2 Trial of CF-301 Complete; Data in 4Q18…

    On September 6, 2018, ContraFect Corp. (CFRX) announced that the Phase 2 trial of CF-301 (exebacase) is fully enrolled. The trial is an international, multicenter, randomized, double blind, placebo controlled study with a superiority comparison between CF-301 or placebo combined with the standard of care antibiotics. The study was expected to enroll approximately 115 patients randomized 3:2 to receive a single dose of 0.25 mg/kg CF-301 administered via a two-hour infusion or placebo along with standard of care antibiotics.

  • GlobeNewswire27 days ago

    ContraFect to Present at Two Upcoming Investor Conferences

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chairman and Chief Executive Officer, will present at two upcoming investor conferences. The Company will provide a corporate overview at the Ladenburg Thalmann Healthcare Conference at 1:00 pm ET on October 2, 2018 and at the Cantor Fitzgerald Global Healthcare Conference at 8:00 am ET on October 3, 2018, both in New York, NY.

  • GlobeNewswirelast month

    ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has completed enrollment in the Phase 2 clinical trial evaluating its first-in-class lysin, CF-301, as a potential treatment for Staphylococcus aureus (Staph aureus) bacteremia including endocarditis. "We are very pleased to have completed enrollment of this Phase 2 superiority study, which is a major milestone in the development of exebacase (CF-301) as a potential new treatment option for patients with Staph aureus bacteremia including endocarditis.

  • GlobeNewswire2 months ago

    ContraFect to Present at Two Upcoming Investor Conferences

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that senior management will present at two upcoming investor conferences. The Company will provide a corporate overview at the Baird Global Healthcare Conference at 2:00 pm ET on September 5, 2018 and at the Janney Montgomery Scott Healthcare Conference at 8:15 am ET on September 17, 2018. ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.

  • GlobeNewswire2 months ago

    ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, has been invited by the Food and Drug Administration (FDA) to participate in a panel discussion for a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”. The public workshop will be held August 21st, 2018 and August 22nd, 2018 at the FDA’s White Oak campus in Silver Spring, MD.

  • Zacks Small Cap Research2 months ago

    CFRX: Data from Phase 2 Trial of CF-301 in 4Q18…

    ContraFect Corp. (CFRX) is currently conducting a Phase 2 clinical trial of CF-301, the company’s lead lysin product candidate, in patients with bacteremia, including those with endocarditis, which is caused by both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains of Staphylococcus aureus. The trial is an international, multicenter, randomized, double blind, placebo controlled study with a superiority comparison between CF-301 or placebo combined with the standard of care antibiotics. The company is not planning to perform an interim analysis.

  • Associated Press2 months ago

    ContraFect: 2Q Earnings Snapshot

    The Yonkers, New York-based company said it had a loss of 27 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results met Wall Street expectations. The average ...

  • GlobeNewswire2 months ago

    ContraFect Announces Second Quarter 2018 Financial Results

    YONKERS, N.Y., Aug. 09, 2018-- ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant ...

  • GlobeNewswire3 months ago

    ContraFect Corporation Prices $10 Million Public Offering of Common Stock

    ContraFect Corporation (CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect.

  • GlobeNewswire3 months ago

    ContraFect Corporation Announces Proposed Public Offering of Common Stock

    ContraFect Corporation (CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares in the offering are to be sold by ContraFect. Piper Jaffray & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering.

  • Zacks Small Cap Research4 months ago

    CFRX: Developing Gram-Negative Lysin Targeting P. aeruginosa

    In June 2018, ContraFect Corp. (CFRX) had multiple presentations at the American Society for Microbiology (ASM) Microbe 2018 on the company’s lead drug candidate CF-301 and the Gram-negative lysin discovery program. This study was undertaken as part of ContraFect’s Gram-negative lysin discovery program. Gram-negative (GN) bacteria are responsible for a number of different bacterial infections and the emergence of antibiotic resistant strains is leading to a potential public health crisis.

  • PR Newswire4 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • Business Wire5 months ago

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX)

    Glancy Prongay & Murray LLP continues its investigation on behalf of ContraFect Corporation investors concerning the Company and its directors’ and officers’ possible violations of state laws.

  • Zacks Small Cap Research5 months ago

    CFRX: Multiple Presentations on CF-301 at ECCMID

    The catheter was removed as part of the patient’s care and segmented into different treatment groups: CF-301, daptomycin, or CF-301 + daptomycin with each compound used at concentrations of 1 μg/mL (a clinically relevant dose), 10 μg/mL, or 100 μg/mL. This study involved the use of an aortic valve infective endocarditis (IE) model in rabbits using methicillin-resistant Staphylococcus aureus (MRSA) strain MW2.

  • Associated Press5 months ago

    ContraFect: 1Q Earnings Snapshot

    On a per-share basis, the Yonkers, New York-based company said it had a loss of 26 cents. Losses, adjusted for non-recurring costs, were 9 cents per share. The results matched Wall Street expectations. ...

  • PR Newswire6 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • Business Wire7 months ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)

    Glancy Prongay & Murray LLP announces an investigation on behalf of ContraFect Corporation investors concerning the Company and its directors’ and officers’ possible violations of state laws.

  • ACCESSWIRE7 months ago

    Free Post Earnings Research Report: Incyte’s Quarterly Sales 36% Surged

    Stock Monitor: ContraFect Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free earnings report on Incyte Corp. (NASDAQ: INCY ). If you want access ...

  • Zacks Small Cap Research7 months ago

    CFRX: No Safety Issues Noted Thus Far in Phase 2 Trial of CF-301

    ContraFect Corp. (CFRX) is currently conducting a Phase 2 clinical trial of CF-301, the company’s lead lysin product candidate, in patients with bacteremia, including those with endocarditis, which is caused by both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains of Staphylococcus aureus. The trial is an international, multicenter, randomized, double blind, placebo controlled study with a superiority comparison between CF-301 or placebo combined with the standard of care antibiotics. The company is not planning to perform an interim analysis.

  • Lysins plus antibiotics: A cure for human bacterial infections?
    Reuters Videos4 months ago

    Lysins plus antibiotics: A cure for human bacterial infections?

    Scientists in New York have found that a protein called lysin extracted from bacteriophage could lead to life-saving medicine to combat antibiotic-resistant infections. The drugs have reached the first human trials, after decades of research. Roselle Chen reports.